Literature DB >> 22740913

Expression of c-Kit and PDGFRα in epithelial ovarian tumors and tumor stroma.

Cunjian Yi1, Li Li, Keming Chen, Shengrong Lin, Xiangqiong Liu.   

Abstract

The purpose of this study was to investigate the expression of c-Kit and platelet-derived growth factor receptor α (PDGFRα) in epithelial ovarian tumor cells and tumor stroma. The expression of c-Kit and PDGFRα in 71 malignant or benign epithelial ovarian tumor tissues and 20 normal ovarian tissues was evaluated by immunohistochemical staining. The expression of c-Kit and PDGFRα in 71 malignant epithelial ovarian tumors and tumor stroma tissue samples was analyzed. A significant increase (P<0.01) of c-Kit expression was observed in malignant ovarian tumors (50.7%) when compared to normal ovarian tissues (10.0%) or benign ovarian tumors (20.0%). The PDGFRα expression rate in malignant ovarian tumors (63.4%) was also significantly higher (P<0.01) than that in normal ovarian tissues (15.0%) or benign ovarian tumors (25.0%). c-Kit was expressed in only 4.2% of the tumor stroma samples, which was significantly lower than the expression of malignant ovarian tumors (P<0.01), whereas the PDGFRα expression in tumor stroma (87.3%) was significantly higher than that of the malignant ovarian tumors (P<0.01). The expression levels of c-Kit and PDGFRα are higher in the malignant ovarian tumors than in the benign ovarian tumors or normal tissues. In the malignant ovarian tumor stroma, c-Kit expression is low and PDGFRα expression is high, and the differential changes of c-kit and PDGFRα suggest distinct roles in ovarian cancer.

Entities:  

Year:  2011        PMID: 22740913      PMCID: PMC3362653          DOI: 10.3892/ol.2011.481

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  18 in total

1.  KIT in ovarian carcinoma: disillusion about a potential therapeutic target.

Authors:  Gad Singer; Peter Schraml; Christopher Belgard; Anna Raggi; Stephan Dirnhofer; Philip Went; Michael J Mihatsch; Holger Moch
Journal:  J Natl Cancer Inst       Date:  2003-07-02       Impact factor: 13.506

2.  Paraffin section detection of the c-kit gene product (CD117) in human tissues: value in the diagnosis of mast cell disorders.

Authors:  D A Arber; R Tamayo; L M Weiss
Journal:  Hum Pathol       Date:  1998-05       Impact factor: 3.466

3.  Effect of platelet-derived growth factor receptor-beta inhibition with STI571 on radioimmunotherapy.

Authors:  Janina Baranowska-Kortylewicz; Michio Abe; Kristian Pietras; Zbigniew P Kortylewicz; Takashi Kurizaki; Jessica Nearman; Janna Paulsson; R Lee Mosley; Charles A Enke; Arne Ostman
Journal:  Cancer Res       Date:  2005-09-01       Impact factor: 12.701

Review 4.  Clinical implications of c-Kit mutations in acute myelogenous leukemia.

Authors:  Muriel Malaise; Daniel Steinbach; Selim Corbacioglu
Journal:  Curr Hematol Malig Rep       Date:  2009-04       Impact factor: 3.952

5.  Phase II trial of imatinib maintenance therapy after irinotecan and cisplatin in patients with c-Kit-positive, extensive-stage small-cell lung cancer.

Authors:  Bryan J Schneider; Gregory P Kalemkerian; Nithya Ramnath; Michael J Kraut; Antoinette J Wozniak; Francis P Worden; John C Ruckdeschel; Xiaohui Zhang; Wei Chen; Shirish M Gadgeel
Journal:  Clin Lung Cancer       Date:  2010-07-01       Impact factor: 4.785

6.  Expression of c-ABL, c-KIT, and platelet-derived growth factor receptor-beta in ovarian serous carcinoma and normal ovarian surface epithelium.

Authors:  Rosemarie E Schmandt; Russell Broaddus; Karen H Lu; Hyun Shvartsman; Angela Thornton; Anais Malpica; Charlotte Sun; Diane C Bodurka; David M Gershenson
Journal:  Cancer       Date:  2003-08-15       Impact factor: 6.860

7.  Imatinib mesylate (Gleevec) inhibits ovarian cancer cell growth through a mechanism dependent on platelet-derived growth factor receptor alpha and Akt inactivation.

Authors:  Daniela Matei; David D Chang; Meei-Huey Jeng
Journal:  Clin Cancer Res       Date:  2004-01-15       Impact factor: 12.531

8.  Characterization of bovine ovarian surface epithelium and stromal cells: identification of secreted proteins.

Authors:  J L Vigne; L L Halburnt; M K Skinner
Journal:  Biol Reprod       Date:  1994-12       Impact factor: 4.285

9.  Expression of platelet-derived growth factor and activated receptor in clinical specimens of epithelial ovarian cancer and ovarian carcinoma cell lines.

Authors:  Sachin M Apte; Corazon D Bucana; Jerald J Killion; David M Gershenson; Isaiah J Fidler
Journal:  Gynecol Oncol       Date:  2004-04       Impact factor: 5.482

10.  ETV1 is a lineage survival factor that cooperates with KIT in gastrointestinal stromal tumours.

Authors:  Ping Chi; Yu Chen; Lei Zhang; Xingyi Guo; John Wongvipat; Tambudzai Shamu; Jonathan A Fletcher; Scott Dewell; Robert G Maki; Deyou Zheng; Cristina R Antonescu; C David Allis; Charles L Sawyers
Journal:  Nature       Date:  2010-10-03       Impact factor: 49.962

View more
  6 in total

1.  A panel of overexpressed proteins for prognosis in esophageal squamous cell carcinoma.

Authors:  Li Shang; Hui-Juan Liu; Jia-Jie Hao; Yan-Yi Jiang; Feng Shi; Yu Zhang; Yan Cai; Xin Xu; Xue-Mei Jia; Qi-Min Zhan; Ming-Rong Wang
Journal:  PLoS One       Date:  2014-10-22       Impact factor: 3.240

2.  Expression and significance of transforming growth factor-β1 in epithelial ovarian cancer and its extracellular matrix.

Authors:  Keming Chen; Hua Wei; Shengrong Ling; Cunjian Yi
Journal:  Oncol Lett       Date:  2014-08-14       Impact factor: 2.967

3.  Establishment of an orthotopic transplantation tumor model in nude mice using a drug-resistant human ovarian cancer cell line with a high expression of c-Kit.

Authors:  Cunjian Yi; Lei Zhang; Li Li; Xiangqiong Liu; Shengrong Ling; Fayun Zhang; Wei Liang
Journal:  Oncol Lett       Date:  2014-09-15       Impact factor: 2.967

4.  Progression inference for somatic mutations in cancer.

Authors:  Leif E Peterson; Tatiana Kovyrshina
Journal:  Heliyon       Date:  2017-04-11

5.  Characterization of stem cell and cancer stem cell populations in ovary and ovarian tumors.

Authors:  Seema C Parte; Surinder K Batra; Sham S Kakar
Journal:  J Ovarian Res       Date:  2018-08-18       Impact factor: 4.234

6.  CD117 expression in operable oesophageal squamous cell carcinomas predicts worse clinical outcome.

Authors:  Huijie Fan; Yuan Yuan; Junsheng Wang; Fuyou Zhou; Mingzhi Zhang; Karl-Erik Giercksky; Jahn M Nesland; Zhenhe Suo
Journal:  Histopathology       Date:  2013-04-09       Impact factor: 5.087

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.